GleamWall
中文EN

NYMXF NYMOX PHARMACEUTICAL CORP IFRS

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY49.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-701.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,135.9%
Debt / equity—
Current ratio0.09x
Interest coverage-18.95x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-295.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q4*2024-12-312024Q32024-09-302023Q4*2023-12-312023Q3*2023-09-302023Q2*2023-06-302023Q1*2023-03-312022Q4*2022-12-312022Q3*2022-09-30
Income statement
Revenue—$0$0$0$0$0$0$0
Cost of revenue—$0$0$0$0$0$0$0
Gross profit—$0$0$0$0$0$0$0
R&D expense$624,000$511,000$2.02M$661,000$594,000$720,000-$2.26M$892,000
SG&A expense$164,000$142,000$2.83M$353,000$505,000$665,000$590,000$586,000
Interest expense$86,000$63,000$25,000$22,000$10,000$2,000-$44,000$10,000
Pretax income-$857,000-$716,000-$5.31M-$1.04M-$1.11M-$1.39M-$1.34M-$1.49M
Net income-$857,000—-$5.31M-$6.03M$3.88M-$1.39M-$1.34M-$1.49M
EPS (basic)———————-0.02
EPS (diluted)———————-0.02
Balance sheet
Cash & equivalents$74,000$41,000$70,000$76,000$132,000$351,000$1.40M$2.70M
Receivables$0—$0———$0—
Inventory——————$0$34,000
Current assets$653,000$623,000$625,000$654,000$214,000$461,000$1.46M$2.91M
PP&E, netmay include right-of-use assets (IFRS)$1,000$1,000$2,000$5,000$8,000$10,000$10,000$13,000
Total assets$654,000$624,000$627,000$669,000$271,000$575,000$1.62M$3.14M
Current liabilities$7.43M$6.92M$3.80M$2.57M$3.15M$2.37M$2.11M$2.36M
Total liabilities$7.43M$6.92M$3.80M$2.57M$3.15M$2.37M$2.11M$2.37M
Shareholders' equity-$6.78M-$6.30M-$3.17M-$1.90M-$2.88M-$1.80M-$482,000$773,000
Shares outstanding94.54M93.54M93.54M93.27M91.27M90.52M90.52M91.27M
Cash flow statement
Operating cash flow-$717,000—-$897,000-$1.26M-$909,000-$988,000-$1.25M-$1.31M
Capital expenditure$0—$0$0$0$3,000$0$0
Free cash flow-$717,000—-$897,000-$1.26M-$909,000-$991,000-$1.25M-$1.31M
Investing cash flow$0—$0$0$0-$3,000$0$0
Financing cash flow$750,000—$891,000$1.21M$690,000-$61,000-$52,000-$60,000
Stock-based compensation$159,000—$3.24M$11,000$32,000$70,000$84,000$33,000

Free plan shows the latest 8 periods; Pro shows all 30 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.